MA33280B1 - Solid product - Google Patents

Solid product

Info

Publication number
MA33280B1
MA33280B1 MA34358A MA34358A MA33280B1 MA 33280 B1 MA33280 B1 MA 33280B1 MA 34358 A MA34358 A MA 34358A MA 34358 A MA34358 A MA 34358A MA 33280 B1 MA33280 B1 MA 33280B1
Authority
MA
Morocco
Prior art keywords
solid product
superior
symbol
iii
salt
Prior art date
Application number
MA34358A
Other languages
Arabic (ar)
French (fr)
Inventor
Wataru Hoshina
Makoto Fukuta
Shigeyuki Marunaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33280(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA33280B1 publication Critical patent/MA33280B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention a pour objet une préparation solide comprenant (i) un composé représenté par la formule (I), chaque symbole étant tel que défini dans la description, ou un sel de celui-ci, (ii) un alcool de sucre, et (iii) un antagoniste du calcium, qui est supérieur du point de vue de la propriété de dissolution et de la stabilité.The present invention relates to a solid preparation comprising (i) a compound represented by the formula (I), each symbol being as defined in the description, or a salt thereof, (ii) a sugar alcohol, and (iii) a calcium antagonist, which is superior in dissolution property and stability.

MA34358A 2009-04-30 2010-04-28 Solid product MA33280B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24
PCT/JP2010/057923 WO2010126168A2 (en) 2009-04-30 2010-04-28 Solid preparation

Publications (1)

Publication Number Publication Date
MA33280B1 true MA33280B1 (en) 2012-05-02

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34358A MA33280B1 (en) 2009-04-30 2010-04-28 Solid product

Country Status (24)

Country Link
EP (1) EP2424501A2 (en)
JP (1) JP5666471B2 (en)
KR (1) KR101797776B1 (en)
CN (1) CN102481248B (en)
AU (1) AU2010242308A1 (en)
BR (1) BRPI1014388A2 (en)
CA (1) CA2760073A1 (en)
CL (1) CL2011002662A1 (en)
CO (1) CO6470841A2 (en)
CR (1) CR20110581A (en)
DO (1) DOP2011000329A (en)
EA (1) EA201171329A1 (en)
EC (1) ECSP11011494A (en)
GE (1) GEP20135940B (en)
IL (1) IL215962A0 (en)
MA (1) MA33280B1 (en)
MX (1) MX2011011011A (en)
MY (1) MY158158A (en)
NZ (1) NZ596395A (en)
PE (1) PE20120315A1 (en)
SG (1) SG175794A1 (en)
TW (1) TWI438201B (en)
WO (1) WO2010126168A2 (en)
ZA (1) ZA201108375B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (en) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition,
KR101535586B1 (en) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban
WO2016122256A1 (en) * 2015-01-30 2016-08-04 씨제이헬스케어 주식회사 Pharmaceutical composition comprising candesartan and amlodipine
CN106668016B (en) * 2015-11-11 2020-06-23 江苏先声药业有限公司 Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof
JP2017210435A (en) * 2016-05-25 2017-11-30 ダイト株式会社 Method for producing irbesartan and amlodipine besylate-containing tablet
JP2019001782A (en) * 2017-06-14 2019-01-10 東和薬品株式会社 Bilayer tablet
JP7101464B2 (en) * 2017-09-28 2022-07-15 エルメッド株式会社 A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same.
CN108210472A (en) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 A kind of Cilnidipine solid dispersions tablet and preparation method thereof
CN108685925B (en) * 2018-05-15 2019-12-06 徐州医科大学 application of compound AB-38b in preparation of medicine for treating diabetic nephropathy
JP2020075869A (en) * 2018-11-05 2020-05-21 日本ケミファ株式会社 Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients
JP2020090471A (en) * 2018-12-07 2020-06-11 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7206872B2 (en) * 2018-12-07 2023-01-18 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7441105B2 (en) * 2020-03-31 2024-02-29 日本ジェネリック株式会社 Film-coated tablets containing azilsartan and amlodipine besilate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (en) * 1988-02-03 1998-10-22 吉富製薬株式会社 Pharmaceutical composition with improved dissolution
JP3057471B2 (en) * 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
WO2002074340A1 (en) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Insulin resistance improving agents
AU2003235395A1 (en) * 2002-05-22 2003-12-02 Shionogi And Co., Ltd. Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical Thiazoline derivative and use of the same
WO2005058823A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
JP2006321726A (en) * 2005-05-17 2006-11-30 Sysmex Corp Method for controlling elution property of tablet
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical
EP1898951B1 (en) * 2005-06-27 2013-02-27 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005031577A1 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist
BRPI0809205B8 (en) * 2007-03-29 2021-05-25 Daiichi Sankyo Co Ltd pharmaceutical composition
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition

Also Published As

Publication number Publication date
EP2424501A2 (en) 2012-03-07
TWI438201B (en) 2014-05-21
CL2011002662A1 (en) 2012-06-15
ZA201108375B (en) 2013-01-30
WO2010126168A2 (en) 2010-11-04
ECSP11011494A (en) 2011-12-30
KR101797776B1 (en) 2017-11-14
DOP2011000329A (en) 2011-11-15
PE20120315A1 (en) 2012-04-07
CA2760073A1 (en) 2010-11-04
NZ596395A (en) 2013-06-28
KR20120026060A (en) 2012-03-16
MY158158A (en) 2016-09-15
TW201041873A (en) 2010-12-01
CN102481248A (en) 2012-05-30
IL215962A0 (en) 2012-01-31
BRPI1014388A2 (en) 2016-04-05
WO2010126168A3 (en) 2011-03-03
GEP20135940B (en) 2013-10-10
SG175794A1 (en) 2011-12-29
JP2012525323A (en) 2012-10-22
EA201171329A1 (en) 2012-05-30
AU2010242308A1 (en) 2011-12-01
CN102481248B (en) 2013-12-11
CR20110581A (en) 2012-01-19
CO6470841A2 (en) 2012-06-29
MX2011011011A (en) 2011-11-02
JP5666471B2 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
MA33280B1 (en) Solid product
MA34713B1 (en) BICYCLIC COMPOUND
MA39247A1 (en) 2- (4-Guanidinophenyl) -2-oxo-ethyl substituted enteropeptidase inhibitors useful for treatment or prevention, e.g. Obesity, diabetes mellitus, eating disorders, hyperlipidemia, hypertension, heart failure
MA32911B1 (en) BENZOTHIAZOLE DERIVATIVES AS AGENTS ANTICANCER AGENTS
MA33240B1 (en) BETA-SECRETASE INHIBITORS
ME01284B (en) Organic compounds
MA31759B1 (en) AMIDE COMPOUND
MA38472A1 (en) Peptide compound
MA31189B1 (en) Molten cycle compounds as partial antagonists of ppar-gamma.
MA33224B1 (en) Proline derivatives as catecin inhibitors
MA33275B1 (en) HIV inhibitors
MA38404A1 (en) New pyridine derivatives
EA201171246A1 (en) COMPOSITION-CONTAINING COMPOSITION, ITS OBTAINING AND APPLICATION
MA38218A1 (en) Pyridine-2-amides useful as cb2 agonists
EA200970247A1 (en) METHOD OF OPTIMIZATION
EA201170168A1 (en) COMPLEX (MINERAL-AMINO ACID) - POLYSACCHARIDE
NO20072494L (en) Solid pharmaceutical compound comprising donepezil hydrochloride
UA92025C2 (en) Indole compounds
MA35172B1 (en) Pesticular mixtures containing isoxazoline derivatives
EA200601279A1 (en) PIPERIDINILKARBONILPYRROLIDINES AND THEIR APPLICATION AS AGANISTS OF MELANOCORTIN
FR2911339B1 (en) FURAZANE DERIVATIVES, THEIR PREPARATION AND THE ENERGY COMPOSITIONS CONTAINING SAME
MA30134B1 (en) PACKAGED CONCENTRATE FOR PREPARING A BROTH, SOUP, SAUCE, JUICE OR TO USE AS A SEASONING, THE CONCENTRATE CONTAINING MODIFIED STARCH
UY33550A (en) FUNGICIDE COMPOSITIONS CONTAINING TRIAZOLILMETILOXIRANO
CR20110360A (en) DERIVATIVES OF 2-PIRIDIN-2-IL-PIRAZOL-3- (2H) -ONA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
FR2915382B1 (en) USE OF AN ACTIVE INGREDIENT FROM MAIZE (ZEA MAYS L) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CYTOCHROME C